HOOKIPA PHARMA INC (HOOK)

Company Profile

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 156 full-time employees. The company went IPO on 2019-04-18. The firm is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-300 is in development for the treatment of prostate cancer and is in an ongoing Phase II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers.

Company Info

HOOKIPA PHARMA INC

The Empire State Building, 350 Fifth Avenue, Room/Suite 7240

New York City NEW YORK 10118

P: 114318906360

CEO: Joern Aldag

Employees: 156

Website: https://www.hookipapharma.com/